Understand the source comparison
Do Peptides Help with Metabolism Boost: Key Compounds and Mechanisms Comparison
GHRP-2, GHRP-6, Ipamorelin GHS-R1a receptor agonism → endogenous GH release 8–15% increase in resting metabolic rate; 300–700% GH elevation within 30 min University of Copenhagen (2022), University of Virginia (2020) Most consistent metabolic outcomes; mimics
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- GHRP-2, GHRP-6, Ipamorelin
- GHS-R1a receptor agonism → endogenous GH release
- 8–15% increase in resting metabolic rate; 300–700% GH elevation within 30 min
- University of Copenhagen (2022), University of Virginia (2020)
- Most consistent metabolic outcomes; mimics natural GH pulsatility without axis suppression
- Hexarelin
- Dual GHS-R1a + CD36 receptor activity
- GH release + direct myocardial effects; 12% REE increase; cardioprotective in preclinical models
- Journal of Endocrinology (2019)
- Broader receptor activity than standard GHRPs; under investigation for metabolic + cardiac applications
- Thymalin (thymus peptide)
- T4 → T3 peripheral conversion enhancement
- 18% increase in circulating T3 without TSH elevation; improved thermogenesis markers
- Journal of Endocrinology (2021)
- Thyroid-mediated metabolism support; complementary to GH pathways
- GLP-1 Analogs (Semaglutide)
- GLP-1 receptor agonism → insulin sensitivity + gastric emptying delay
- Indirect metabolic improvement via reduced hepatic glucose output; 9.2 mg/dL fasting glucose reduction
- NEJM STEP-1 Trial (2021)
- Primarily glucose regulation; metabolic benefit secondary to insulin sensitivity restoration
- MK-677 (Ibutamoren)
- Ghrelin receptor agonist (oral bioavailability)
- Sustained GH + IGF-1 elevation; 12–18% REE increase in multi-week protocols
- Clinical Endocrinology (2018)
- Non-peptide ghrelin mimetic; longer half-life than injectable GHRPs; comparable metabolic outcomes